Literature DB >> 29086923

The non-neuronal and nonmuscular effects of botulinum toxin: an opportunity for a deadly molecule to treat disease in the skin and beyond.

S A Grando1, C B Zachary1.   

Abstract

There is growing evidence that botulinum neurotoxins (BoNTs) exhibit biological effects on various human cell types with a host of associated clinical implications. This review aims to provide an update on the non-neuronal and nonmuscular effects of botulinum toxin. We critically analysed recent reports on the structure and function of cellular signalling systems subserving biological effects of BoNTs. The BoNT receptors and intracellular targets are not unique for neurotransmission. They have been found in both neuronal and non-neuronal cells, but there are differences in how BoNT binds to, and acts on, neuronal vs. non-neuronal cells. The non-neuronal cells that express one or more BoNT/A-binding proteins, and/or cleavage target synaptosomal-associated protein 25, include: epidermal keratinocytes; mesenchymal stem cells from subcutaneous adipose; nasal mucosal cells; urothelial cells; intestinal, prostate and alveolar epithelial cells; breast cell lines; neutrophils; and macrophages. Serotype BoNT/A can also elicit specific biological effects in dermal fibroblasts, sebocytes and vascular endothelial cells. Nontraditional applications of BoNT have been reported for the treatment of the following dermatological conditions: hyperhidrosis, Hailey-Hailey disease, Darier disease, inversed psoriasis, aquagenic palmoplantar keratoderma, pachyonychia congenita, multiple eccrine hydrocystomas, eccrine angiomatous hamartoma, eccrine sweat gland naevi, congenital eccrine naevus, Raynaud phenomenon and cutaneous leiomyomas. Experimental studies have demonstrated the ability of BoNT/A to protect skin flaps, facilitate wound healing, decrease thickness of hypertrophic scars, produce an anti-ageing effect, improve a mouse model of psoriasiform dermatitis, and have also revealed extracutaneous effects of BoNT arising from its anti-inflammatory and anticancer properties. BoNTs have a much wider range of applications than originally understood, and the individual cellular responses to the cholinergic impacts of BoNTs could provide fertile ground for future studies.
© 2017 British Association of Dermatologists.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29086923     DOI: 10.1111/bjd.16080

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN: 0007-0963            Impact factor:   9.302


  12 in total

1.  Blocking Neuronal Signaling to Immune Cells Treats Streptococcal Invasive Infection.

Authors:  Felipe A Pinho-Ribeiro; Buket Baddal; Rianne Haarsma; Maghnus O'Seaghdha; Nicole J Yang; Kimbria J Blake; Makayla Portley; Waldiceu A Verri; James B Dale; Michael R Wessels; Isaac M Chiu
Journal:  Cell       Date:  2018-05-10       Impact factor: 41.582

2.  Distinctions in the Management, Patient Impact, and Clinical Profiles of Pachyonychia Congenita Subtypes.

Authors:  Albert G Wu; Shari R Lipner
Journal:  Skin Appendage Disord       Date:  2021-02-05

Review 3.  Variability of Botulinum Toxins: Challenges and Opportunities for the Future.

Authors:  Christine Rasetti-Escargueil; Emmanuel Lemichez; Michel R Popoff
Journal:  Toxins (Basel)       Date:  2018-09-13       Impact factor: 4.546

4.  New trends in botulinum toxin use in dermatology.

Authors:  Stefania Guida; Francesca Farnetani; Steven P Nisticò; Caterina Giorgio Mariarosaria; Graziella Babino; Giovanni Pellacani; Elisabetta Fulgione
Journal:  Dermatol Pract Concept       Date:  2018-10-31

Review 5.  Engineering Botulinum Toxins to Improve and Expand Targeting and SNARE Cleavage Activity.

Authors:  Elena Fonfria; Mark Elliott; Matthew Beard; John A Chaddock; Johannes Krupp
Journal:  Toxins (Basel)       Date:  2018-07-04       Impact factor: 4.546

6.  The effect of botulinum toxin type A in different dilution on the contraction of fibroblast-In vitro study.

Authors:  Rungsima Wanitphakdeedecha; Arisa Kaewkes; Chanida Ungaksornpairote; Saowalak Limsaengurai; Uraiwan Panich; Woraphong Manuskiatti
Journal:  J Cosmet Dermatol       Date:  2019-07-22       Impact factor: 2.696

Review 7.  Engineering Botulinum Neurotoxins for Enhanced Therapeutic Applications and Vaccine Development.

Authors:  Christine Rasetti-Escargueil; Michel R Popoff
Journal:  Toxins (Basel)       Date:  2020-12-22       Impact factor: 4.546

8.  Botulinum toxin injections as an effective treatment for patients with intertriginous Hailey-Hailey or Darier disease: an open-label 6-month pilot interventional study.

Authors:  Isabelle Dreyfus; Aude Maza; Lauriane Rodriguez; Margot Merlos; Hélène Texier; Vanessa Rousseau; Agnès Sommet; Juliette Mazereeuw-Hautier
Journal:  Orphanet J Rare Dis       Date:  2021-02-18       Impact factor: 4.123

9.  Therapeutic Use of Botulinum Neurotoxins in Dermatology: Systematic Review.

Authors:  Emanuela Martina; Federico Diotallevi; Giulia Radi; Anna Campanati; Annamaria Offidani
Journal:  Toxins (Basel)       Date:  2021-02-05       Impact factor: 4.546

Review 10.  Toxicology and pharmacology of botulinum and tetanus neurotoxins: an update.

Authors:  Marco Pirazzini; Cesare Montecucco; Ornella Rossetto
Journal:  Arch Toxicol       Date:  2022-03-25       Impact factor: 6.168

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.